Research programme: Tau protein inhibitor - Medifron
Latest Information Update: 13 Jul 2022
At a glance
- Originator Medifron DBT
- Class Antidementias
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 16 Jun 2022 Preclinical trials in Alzheimer's disease in South Korea (unspecified route)